Morgan Stanley assumed coverage on shares of Clementia Pharm (NASDAQ:CMTA) in a research report report published on Monday morning, reports. The firm issued an overweight rating and a $27.00 target price on the stock.

Shares of Clementia Pharm (NASDAQ CMTA) opened at 16.33 on Monday. The firm’s market capitalization is $498.51 million. The stock’s 50 day moving average price is $16.04 and its 200-day moving average price is $15.21. Clementia Pharm has a 52-week low of $15.05 and a 52-week high of $18.95.

ILLEGAL ACTIVITY NOTICE: “Clementia Pharm (CMTA) Receives New Coverage from Analysts at Morgan Stanley” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright law. The correct version of this report can be read at

Clementia Pharm Company Profile

Clementia Pharmaceuticals Inc is a clinical stage biopharmaceutical company. The Company is engaged in developing disease-modifying treatments for patients suffering from debilitating bone and other diseases with high unmet medical need. Its lead product candidate, palovarotene, is an oral small molecule that binds and activates retinoic acid receptor gamma (an RARg agonist), and has activity in preventing abnormal new bone formation as well as scar tissue formation (or fibrosis) in a variety of tissues in animal models.

Receive News & Stock Ratings for Clementia Pharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clementia Pharm and related stocks with our FREE daily email newsletter.